The U.S. FDA has selected Icon to validate three patient-reported outcome (PRO) instruments used to assess clinical endpoints in antibacterial drug trials. With the help of the Biomarkers Consortium ...
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that ...
Analyst Derik De Bruin of Bank of America Securities maintained a Buy rating on Icon (ICLR – Research Report), with a price target of $275.00. Derik De Bruin’s buy rating for Icon’s stock is ...
ALLSCHWIL, Switzerland, March 29, 2022 /PRNewswire/ -- BioCopy AG introduces ValidaTe, an innovative, proprietary platform based on microarrays for the highly parallelized screening of drug candidates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback